Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migraines geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Impel Neuropharma raises $80M in Washington state’s first IPO of 2021
April 23, 2021 at 7:36 am
Impel CEO Adrian Adams. (Impel Photo)
The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday under the ticker IMPL. It is the first Washington state company to go public in 2021 via a traditional IPO.
Company background: Founded in 2008, Impel is a late-stage pre-revenue pharma company that develops drugs for central nervous system disorders such as migraines and Parkinson’s. It is known for its Precision Olfactory Delivery (POD) platform, which sends drugs into the nasal cavity with the goal of penetrating the blood-brain barrier and targeting the organ more directly than is possible with pills or injected drugs. Its lead candidate, a drug that treats migraines called TRUDHESA, is going through the FDA’s New Drug Application process.
Seattle biotech firm Impel NeuroPharma files for $75M IPO
April 5, 2021 at 8:41 am News Brief
Impel CEO Adrian Adams. (Impel Photo)
Seattle-based biotech company Impel NeuroPharma is set to go public. The company, which develops central nervous system disorders such as migraines and Parkinson’s, submitted paperwork on Friday for a $75 million IPO.
Founded in 2008, Impel is a late-stage pre-revenue pharma company known for its Precision Olfactory Delivery (POD) platform, which sends drugs into the nasal cavity with the goal of penetrating the blood-brain barrier and targeting the organ more directly than is possible with pills or injected drugs. Its lead candidate, a drug that treats migraines called TRUDHESA, is going through the FDA’s New Drug Application process.